Tower Research Capital LLC (Trc) Cyclo Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 4,999 shares of CYTH stock, worth $3,949. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,999
Previous 6,582
24.05%
Holding current value
$3,949
Previous $9,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CYTH
# of Institutions
23Shares Held
2.24MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA817KShares$645,6430.39% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$379,75972.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA447KShares$352,7920.0% of portfolio
-
Geode Capital Management, LLC Boston, MA175KShares$138,5800.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$86,918100.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $6.67M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...